Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the establishment of a partnership with Fusion Antibodies Services that will combine core technologies of the two companies allowing customers to link monoclonal antibody (MAb) humanization programs with the generation of high performing and fully documented CHO cell lines.
Customers will be able to seamlessly go from non-human MAbs to clinical candidate generated in a cGMP ready CHO cell line in 8 months. Clinical candid ...
Satisfied Users & 
Approved Press Releases
